There cannot be one set of rules for GLP-1compounding and another set of rules for other drug products.
As a result, the narrow exceptions that compounders want to expand would cross critical boundaries that FDA needs to preserve.
www.fdamatters.com/fdamatters/a...
#FDA #FDAMatters #compounding